Sugi Predict

Sugi Predict / Compounds / SCHEMBL1223596

SCHEMBL1223596

SCHEMBL1223596

COC(=O)c1cccc2[nH]cc(C)c12

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 11/20 0.61
▸ CREBBP Q92793 1/20 0.55
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ CFTR P13569 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ PDE1C Q14123 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29886596 1.00 NR4A2 (0.61) NR4A2CREBBPLMNATSHRALDH1A1
SCHEMBL9937305 0.87 NR4A2 (0.70) NR4A2CREBBPPDE1CNPC1
SCHEMBL15836985 0.84 TSHR (0.54) NR4A2TSHRALDH1A1HSD17B10KDM4E
SCHEMBL28025060 0.83 NR4A2 (0.57) NR4A2CREBBPLMNATSHRALDH1A1
SCHEMBL5438520 0.83 NR4A2 (0.60) NR4A2CREBBPLMNATSHRALDH1A1
SCHEMBL16686859 0.83 NR4A2 (0.64) NR4A2CREBBPLMNATSHRALDH1A1
SCHEMBL27968725 0.83 NR4A2 (0.64) NR4A2CREBBPLMNATSHRALDH1A1
SCHEMBL2592748 0.81 HSD17B10 (0.47) NR4A2ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL16686899 0.81 NR4A2 (0.58) NR4A2CREBBPLMNAALDH1A1HSD17B10
SCHEMBL29950881 0.80 NR4A2 (0.57) NR4A2CREBBPLMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243160-A1 INDOLE DERIVATIVES FOR TARGETING AUTOPHAGY Automera PTE. LTD (SG) 2025-07-31 — — US disclosed
CN-108137542-B Pyridone dicarboxamides as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-27 — — CN disclosed
WO-2022138791-A1 EP2 ANTAGONIST 小野薬品工業株式会社 2022-06-30 — — WO disclosed
CN-107873030-B 5-HT2CReceptor agonists and compositions and methods of use 艾尼纳制药公司 2021-03-19 — — CN disclosed
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-02-23 — — US disclosed
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-02-23 — — US disclosed
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-10-01 — — US disclosed
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-10-01 — — US disclosed
US-10392390-B2 5-HT2C receptor agonists and compositions and methods of use ARENA PHARMACEUTICALS, INC. (US) 2019-08-27 — — US disclosed
EP-3288946-B1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARM INC (US) 2019-08-21 — — EP disclosed
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-09-13 — — US disclosed
EP-3344615-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2018-07-11 — — EP disclosed
US-20180186797-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARMACEUTICALS, INC. 2018-07-05 — — US disclosed
EP-3288946-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE Arena Pharmaceuticals, Inc. (US) 2018-03-07 — — EP disclosed
WO-2017037116-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-09 — — WO disclosed
WO-2016176177-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARMACEUTICALS, INC. (US) 2016-11-03 — — WO disclosed
WO-2015066344-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARMACEUTICALS, INC. (US) 2015-05-07 — — WO disclosed
US-20110033393-A1 Hydrazone Compounds and Their Use REDPOINT BIO CORPORATION 2011-02-10 — — US disclosed
WO-2010132615-A1 HYDRAZONE COMPOUNDS AND THEIR USE STEIN PHILIP (US) 2010-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT NR4A2 1171/4885CREBBP 206/4885LMNA 1464/4885
US-10392390-B2 5-HT2C receptor agonists and compositions and methods of use HTR2C, HTR2A, HCRTR2 NR4A2 330/4885CREBBP 1652/4885LMNA 1654/4885
US-20110033393-A1 Hydrazone Compounds and Their Use TRPM5, TRPV5, TRPM8 NR4A2 3726/4885CREBBP 2724/4885LMNA 2883/4885
US-20250243160-A1 INDOLE DERIVATIVES FOR TARGETING AUTOPHAGY SQSTM1, ATG7, BECN1 NR4A2 3001/4885CREBBP 2742/4885LMNA 1131/4885
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT NR4A2 1171/4885CREBBP 206/4885LMNA 1464/4885
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT NR4A2 1171/4885CREBBP 206/4885LMNA 1464/4885
US-20180186797-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE HTR2C, HTR2A, HCRTR2 NR4A2 330/4885CREBBP 1652/4885LMNA 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.